Abstract 1842: Off the shelf CAR T therapy No lymphodepletion needed, delivering robust, targeted CD19+ B cell elimination in multiple in vitro assays @RheumNow #ACR24

Non-pharm tx in TAK - not something we always think about but… Impressive effect of resistance exercise!! Not just in symptoms but also inflammatory markers Per Dr. Springer - even a stress ball could be enough for UE vascular health in these pt @RheumNow #ACR24 https://t.co/3O46gobbMX

• https://x.com/Dr_Brian_MD/status/1858534823310069933/photo/1
• https://x.com/Dr_Brian_MD/status/1858534823310069933/photo/1

Overall very reasonable, aligning ACR recs w/other guidance groups & updated data Remember: guidelines are meant to be broken. Some patients can likely avoid pulse, others may need more steroid on the back end, biopsies are not benign #ACR24 @RheumNow

Recommend "Triple Therapy" = Glucocorticoids + two other agents Practically, that means MMF + belimumumab OR CNI for most pts For the CYC afficionados, the lower-dose EUROLUPUS protocol is preferred #ACR24 @RheumNow https://t.co/0gRISXSw0c

• https://x.com/EBRheum/status/1858535181373563219/photo/1

Happening now, new guidelines for mgmt. A few highlights: Recommend prompt GC therapy, pulse x1-3d followed by oral pred (<0.5mg/kg/d) w/taper to <5mg by 6 months Aligns with EULAR recs for a much-lower dose than most clinicians currently doing #ACR24 @RheumNow https://t.co/B71i7FBYlQ

• https://x.com/EBRheum/status/1858535178517303725/photo/1

Biosimilar switching in practice Hyrich: UK experience Switching to biosimilar has no immediate benefit to patients but saves NHS money Allows for gain share that can be re-invested in pt care Transparency in switching in explaining to pts and offering resource @RheumNow #ACR24

If you’re starting with DMARD (according to ACR/VF guidelines) tx in TAK - MTX and AZA are probably equivalent options… MMF not so much @RheumNow #ACR24 https://t.co/jn52ujtspo

• https://x.com/Dr_Brian_MD/status/1858537546902335997/photo/1

Hyrich: ETN originator vs biosimilar initiation - DAS28 - no signif change at B/L, 6mo, 12 mo. Switch? Matched pts in ETN switch v cont originator - good b/l control on Rx -DAS28 maintained w switch 10% did go back to originator, felt less good tho similar DAS #ACR24 @RheumNow https://t.co/RHRit5CtUu

• https://x.com/ericdeinmd/status/1858537804281626625/photo/1
• https://x.com/ericdeinmd/status/1858537804281626625/photo/1

Older adults with late-onset RA (LORA) with more erosive changes, even with DMARD use But is T2T met? LORA with higher DAS on diagnosis and yet 10% on bDMARD vs 26% of young-onset RA #ACR24 @RheumNow ABST#2224 https://t.co/dYs1JwcJeq

• https://x.com/JihaRheum/status/1858537901757239324/photo/1

#2222 📊 New data on #RA-ILD: 🔴In early RA, ILD prevalence hits 21.4% after 10 years, with 8.2% cumulative incidence at 5 years (IR 14.9/1000 PY). 🔴ILD often precedes or coincides with RA onset. 🔴NSIP > UIP 🔴airway involvement less common than expected. #acr24 @RheumNow